In the analysis of > 2200 breast cancer patients, > 50% of patient’s tumors were CCR5+. and > 95% of triple-negative breast cancer (TNBC) were CCR5+ [12]. This evidence concerns the gene CCR5 and triple-negative breast carcinoma.